News Sentiment

CTSO sentiment intelligence

Cytosorbents Crp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.38 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-2.2% over one week, -4.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -2.2% Price reacting lower
Trend fit Trend inactive -4.6% over four weeks
Fair value -64.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 38
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
TradingKey 6
Zacks Small Cap Research 2
TradingView 2
Finviz 2
Quiver Quantitative 2
DonanımHaber 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 21
Regulatory and legal 2
Guidance 2
Analyst action 2
Balance sheet 1
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Stock Titan Direct company coverage

CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure

CytoSorbents (NASDAQ: CTSO) has received a notice from Nasdaq for non-compliance with the $35 million Market Value of Listed Securities requirement. The company now has 180 calendar days, until December 28, 2026, to regain compliance by maintaining a market value at or above $35

Tone
Negative 27/100
Event
Market update
Published
06 Jul 2026 20:12
Source
Stock Titan
TradingView Direct company coverage

CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard

CytoSorbents (CTSO) received a notice from Nasdaq on June 29, 2026, indicating non-compliance with Listing Rule 5550(b)(2) because its market value of listed securities fell below the $35 million minimum. The company has 180 days, until December 28, 2026, to regain compliance by

Tone
Negative 19/100
Event
Market update
Published
06 Jul 2026 20:12
Source
TradingView
Finviz Direct company coverage

CTSO - Cytosorbents Corp Options

This page provides a detailed financial overview of Cytosorbents Corp (CTSO), including its last trading close, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider and institutional ownership percentages, and price pe

Tone
Negative 39/100
Event
Market update
Published
04 Jul 2026 18:39
Source
Finviz
Quiver Quantitative Direct company coverage

CTSO | Cytosorbents Corp. Executive Compensation

This article provides an overview of Cytosorbents Corp. (CTSO) focusing on executive compensation, insider trading, institutional holdings, government contracts, and patent information. It highlights specific patent grants related to medical technologies and lists federal governm

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 22:09
Source
Quiver Quantitative
Seeking Alpha Direct company coverage

Cytosorbents Corporation (CTSO) Presents at Life Sciences Virtual Investor Forum - Slideshow

Cytosorbents Corporation (CTSO) delivered a presentation at the Life Sciences Virtual Investor Forum. This article is a reproduction of the slide deck presented by the company at the event. The content was prepared by Seeking Alpha's transcripts team.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 19:13
Source
Seeking Alpha
Stock Titan Direct company coverage

[ARS] Cytosorbents Corp SEC Filing

This article announces an ARS SEC filing for Cytosorbents Corp (CTSO), noting a low impact and neutral sentiment. The filing was accepted by the SEC on June 25, 2026, and is available as a PDF. The company's stock overview, recent news, and other SEC filings are also provided.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 22:09
Source
Stock Titan
Stock Titan Direct company coverage

CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing

CytoSorbents (NASDAQ: CTSO) is seeking shareholder approval for a reverse stock split at its upcoming virtual annual meeting on August 13, 2026. This move, with a proposed ratio between 1-for-5 and 1-for-20, is primarily aimed at raising the stock's per-share price to regain comp

Tone
Neutral 50/100
Event
Regulatory and legal
Published
25 Jun 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs

CytoSorbents (CTSO) has announced two FDA pre-submission meetings in August 2026 to advance its ticagrelor and DOAC programs. The company plans a new De Novo submission for ticagrelor removal after the FDA requested additional mechanistic data and will hold a separate meeting for

Tone
Positive 65/100
Event
Market update
Published
25 Jun 2026 13:11
Source
TradingView
Stock Titan Direct company coverage

CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals

CytoSorbents (NASDAQ: CTSO) has detailed its plans for upcoming FDA pre-submission meetings in August 2026 regarding its DrugSorb-ATR device for ticagrelor and DOAC removal, targeting late 2026 or early 2027 De Novo submissions. The company reported $37.1 million in 2025 sales fo

Tone
Positive 63/100
Event
Balance sheet
Published
25 Jun 2026 13:11
Source
Stock Titan
TradingKey Direct company coverage

Cytosorbents Corp (CTSO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Cytosorbents Corp (CTSO), highlighting its current valuation score of 8.74, ranking it 65th in the Healthcare Equipment & Supplies industry. It notes the company's P/E ratio is -2.47, a significant deviation from its recent high and l

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 08:10
Source
TradingKey
TradingKey Direct company coverage

Cytosorbents Corp (CTSO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cytosorbents Corp (CTSO), noting its current price momentum score of 6.32 and suggesting suitability for range-bound swing trading between resistance at 0.57 and support at 0.34. Based on various technical indicators and moving averag

Tone
Negative 36/100
Event
Market update
Published
18 Jun 2026 17:40
Source
TradingKey
Market source Direct company coverage

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

CytoSorbents Corporation announced that its CEO, Dr. Phillip Chan, will present at the Life Sciences Forum on June 24, 2026, to provide an overview and update on the company. Following the presentation, Dr. Chan and CFO Peter Mariani will participate in a Q&A session. The company

Tone
Positive 67/100
Event
Market update
Published
18 Jun 2026 13:10
Source
Market source
TradingKey Direct company coverage

Cytosorbents Corp (CTSO) Institutional Confidence

Cytosorbents Corp (CTSO) has an institutional shareholding score of 3.00, placing it 132nd in its industry, with 25.84% institutional ownership, a 10.95% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.16% of outstanding shares. The

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:10
Source
TradingKey
TradingKey Direct company coverage

Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cytosorbents Corp (CTSO), highlighting its current earnings forecast score of 7.00 and ranking in the Healthcare Equipment & Supplies industry. It details analyst ratings, price targets, and expected EPS and revenue figures. The fore

Tone
Positive 59/100
Event
Earnings
Published
17 Jun 2026 20:10
Source
TradingKey
Investing.com Direct company coverage

Cytosorbents CFO Peter Mariani buys $44,000 in stock

Cytosorbents Corp's CFO, Peter Mariani, purchased 100,000 shares of company stock for $44,000, acquiring them at a weighted average price of $0.44 per share. This insider transaction occurred when the stock was near its 52-week low and analysts anticipate the company will become

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 06:11
Source
Investing.com
Stock Titan Direct company coverage

Cytosorbents (CTSO) CFO Peter Mariani buys 100,000 shares in open market

Cytosorbents Corp's CFO, Peter J. Mariani, purchased 100,000 shares of common stock at a weighted average price of $0.44 per share on June 15, 2026, increasing his direct holdings to 638,113 shares. This open-market transaction signals a positive sentiment from the insider. His h

Tone
Positive 69/100
Event
Market update
Published
16 Jun 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

Cytosorbents (CTSO) CEO boosts stake with 261,469-share open-market buy

Cytosorbents Corp (CTSO) CEO Phillip P. Chan increased his direct holdings by purchasing 261,469 shares in open-market transactions on June 12 and June 15, 2026. He acquired shares at weighted average prices of $0.40 and $0.43 respectively, totaling approximately $104,898. Follow

Tone
Positive 94/100
Event
Deals and strategy
Published
15 Jun 2026 22:39
Source
Stock Titan
Investing.com Direct company coverage

Cytosorbents CEO Phillip Chan buys $104,897 in company stock

Cytosorbents Corp CEO Phillip P. Chan recently purchased $104,897 worth of company stock through open market transactions on June 12 and June 15, 2026. The purchases occurred while the stock was trading near its 52-week low and is considered undervalued by InvestingPro analysis.

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:39
Source
Investing.com
TradingKey Direct company coverage

Cytosorbents Corp (CTSO) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Cytosorbents Corp (CTSO), noting its current score of 6.45, which ranks it 154 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's weak financial status and average operating efficiency. The

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:12
Source
TradingKey
Simply Wall Street Direct company coverage

Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near?

Cytosorbents Corporation (NASDAQ:CTSO) is projected to reach breakeven by 2027, according to analysts, after incurring a final loss in 2026. This would require an average annual growth rate of 77%. The company currently has a high debt-to-equity ratio of over 2x, which poses a ri

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 10:40
Source
Simply Wall Street
Stock Titan Direct company coverage

CytoSorbents (NASDAQ: CTSO) asks shareholders to OK 1-for-5–1-for-20 reverse split

CytoSorbents (NASDAQ: CTSO) is seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-20 at its upcoming Annual Meeting on August 13, 2026. This measure is primarily intended to help the company meet Nasdaq's minimum bid price requirement of $

Tone
Neutral 50/100
Event
Regulatory and legal
Published
11 Jun 2026 20:39
Source
Stock Titan
AD HOC NEWS Direct company coverage

CytoSorbents Corp stock (US23283M1018): Q1 miss keeps focus on growth and cash runway

CytoSorbents Corp reported weaker than expected Q1 2026 revenue of $8.9 million and a larger loss per share of -$0.05, missing analyst estimates. This performance keeps the focus on the company's growth trajectory, its path to profitability, and the demand for its blood purificat

Tone
Negative 31/100
Event
Earnings
Published
09 Jun 2026 12:39
Source
AD HOC NEWS